This is the authors' abstract. We don't add key points for this paper.
Periprostatic adipose tissue (PPAT), a specialized fat depot surrounding the prostate gland, is linked to poor prostate cancer (PCa) prognosis. However, the mechanisms underlying the crosstalk between PPAT and PCa progression remain poorly understood. We found that PCa tumors, particularly aggressive ones, actively stimulated androgen receptor (AR) expression in PPAT, with elevated AR expression and signaling in PPAT being associated with aggressive PCa. Adipocyte-specific AR overexpression was sufficient to promote PCa growth in vitro and in vivo. Mechanistically, AR directly suppressed the E3 ligase RNF213, and RNF213 depletion increased hormone-sensitive lipase (HSL) protein abundance. Consequently, AR-driven lipolysis liberated free fatty acids (FFA) and promoted PCa cell growth and tumor microenvironment remodeling. Clinically, PPAT in high-risk PCa patients exhibited elevated lipolytic activity and reduced RNF213 expression. The PPAT conditioned medium (CM) of high-risk PCa patients enhanced PCa cell proliferation, which was reversed by blocking fatty acid uptake. Targeting this axis with the antilipolytic drug Acipimox significantly attenuated PCa growth in vivo. Our findings support a feed-forward interaction between prostate tumors and adipocyte AR signaling that promotes disease progression. This self-reinforcing cycle accelerates disease progression, and targeting PPAT lipolysis may represent a promising therapeutic strategy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: